Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)

被引:119
作者
Lu, J
Sista, P
Giguel, F
Greenberg, M
Kuritzkes, DR
机构
[1] Harvard Univ, Sch Med, Div Aids, Boston, MA USA
[2] Trimeris Inc, Durham, NC USA
[3] Brigham & Womens Hosp, Sect Retroviral Therapeut, Cambridge, MA 02139 USA
关键词
D O I
10.1128/JVI.78.9.4628-4637.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Resistance to enfuvirtide (ENF; T-20), a fusion inhibitor of human immunodeficiency virus type 1 (HIV-1), is conferred by mutations in the first heptad repeat of the gp41 ectodomain. The replicative fitness of recombinant viruses carrying ENF resistance mutations was studied in growth competition assays. ENF resistance mutations, selected in vitro or in vivo, were introduced into the env gene of HIV-1(NL4-3) by site-directed mutagenesis and expressed in HIV-1 recombinants carrying sequence tags in nef. The doubling time of ENF-resistant viruses was highly correlated with decreasing ENF susceptibility (R-2 = 0.859; P < 0.001). Initial fitness experiments focused on mutants identified by in vitro selection in the presence of ENF (L. T. Rimsky, D. C. Shugars, and T. J. Matthews, J. Virol. 72:986-993, 1998). In the absence of drug, these mutants displayed reduced fitness compared to wild-type virus with a relative order of fitness of wild type > I37T > V38 M > D36S/V38 M; this order was reversed in the presence of ENF. Likewise, recombinant viruses carrying ENF resistance mutations selected in vivo displayed reduced fitness in the absence of ENF with a relative order of wild type > N42T > V38A > N42T/N43K approximate to N42T/N43S > V38A/N42D approximate to V38A/N42T. Fitness and ENF susceptibility were inversely correlated (r = -0.988; P < 0.001). Similar results were obtained with recombinants expressing molecularly cloned full-length env genes obtained from patient-derived HIV-1 isolates before and after ENF treatment. Further studies are needed to determine whether the reduced fitness of ENF-resistant viruses alters their pathogenicity in vivo.
引用
收藏
页码:4628 / 4637
页数:10
相关论文
共 22 条
[1]   A CROSS-SECTIONAL COMPARISON OF PERSONS WITH SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BOZZETTE, SA ;
MCCUTCHAN, JA ;
SPECTOR, SA ;
WRIGHT, B ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06) :1374-1379
[2]   Core structure of gp41 from the HIV envelope glycoprotein [J].
Chan, DC ;
Fass, D ;
Berger, JM ;
Kim, PS .
CELL, 1997, 89 (02) :263-273
[3]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[4]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[5]   Capture of an early fusion-active conformation of HIV-1 gp41 [J].
Furuta, RA ;
Wild, CT ;
Weng, YK ;
Weiss, CD .
NATURE STRUCTURAL BIOLOGY, 1998, 5 (04) :276-279
[6]   STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURE ASSAY FOR DETERMINATION OF DRUG SUSCEPTIBILITIES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
JAPOUR, AJ ;
MAYERS, DL ;
JOHNSON, VA ;
KURITZKES, DR ;
BECKETT, LA ;
ARDUINO, JM ;
LANE, J ;
BLACK, RJ ;
REICHELDERFER, PS ;
DAQUILA, RT ;
CRUMPACKER, CS ;
BALFOUR, H ;
ERICE, A ;
COOMBS, R ;
KATZENSTEIN, D ;
LATHEY, J ;
RICHMAN, D ;
MCINTOSH, K ;
RANGAN, S ;
REICHMAN, R ;
SCOTT, W ;
USSERY, M ;
ABRAMS, L ;
MCCUTCHAN, F ;
BURKE, D ;
GARDNER, L ;
ROBERTS, C ;
CHUNG, R ;
HICKS, C ;
SHELLIE, E ;
FOWLER, A ;
MERRITT, L ;
FUJIMURAJUSTICE, M ;
RUIZ, N ;
WAGNER, K ;
GAIL, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1095-1101
[7]   Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [J].
Kilby, JM ;
Hopkins, S ;
Venetta, TM ;
DiMassimo, B ;
Cloud, GA ;
Lee, JY ;
Alldredge, L ;
Hunter, E ;
Lambert, D ;
Bolognesi, D ;
Mathews, T ;
Johnson, MR ;
Nowak, MA ;
Shaw, GM ;
Saag, MS .
NATURE MEDICINE, 1998, 4 (11) :1302-1307
[8]   DETECTION OF REPLICATION-COMPETENT AND PSEUDOTYPED HUMAN-IMMUNODEFICIENCY-VIRUS WITH A SENSITIVE CELL-LINE ON THE BASIS OF ACTIVATION OF AN INTEGRATED BETA-GALACTOSIDASE GENE [J].
KIMPTON, J ;
EMERMAN, M .
JOURNAL OF VIROLOGY, 1992, 66 (04) :2232-2239
[9]   Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay [J].
Kosalaraksa, P ;
Kavlick, MF ;
Maroun, V ;
Le, R ;
Mitsuya, H .
JOURNAL OF VIROLOGY, 1999, 73 (07) :5356-5363
[10]   A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy [J].
Lalezari, JP ;
Eron, JJ ;
Carlson, M ;
Cohen, C ;
DeJesus, E ;
Arduino, RC ;
Gallant, JE ;
Volberding, P ;
Murphy, RL ;
Valentine, F ;
Nelson, EL ;
Sista, PR ;
Dusek, A ;
Kilby, JM .
AIDS, 2003, 17 (05) :691-698